Beijing, July 11, 2024 – Shineco, Inc. (“Shineco” or the “Company”) (NASDAQ: SISI), a provider of innovative diagnostic medical products and related medical devices, announced today that it has started an underwritten public offering of its common stock and pre-funded warrants to purchase its shares of common stock. The Company is offering all of the common stock and pre-funded warrants, as well as the common stock underlying the pre-funded warrants. This offering is subject to market conditions and other factors, and there is no guarantee that it will be completed, or what the final size or terms of the offering will be.

EF Hutton LLC is serving as the sole book-running manager for the offering.

The Company is offering the common stock and pre-funded warrants pursuant to an effective shelf registration statement on Form S-3 (File No. 333-261229), which was previously filed with the U.S. Securities and Exchange Commission (SEC) and declared effective by the SEC on June 10, 2022, and the accompanying prospectus contained therein.

The offering can only be made through the written prospectus supplement and the accompanying prospectus that are part of the registration statement. A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the public offering have been or will be filed with the SEC and form a part of the effective registration statement.

Copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering can be obtained, when available, on the SEC’s website at  or by contacting EF Hutton LLC Attention: Syndicate Department, 590 Madison Avenue, 39th Floor, New York, NY 10022, by email at , or by telephone at (212) 404-7002. Before investing, you should read the preliminary prospectus supplement and accompanying prospectus, together with the information incorporated therein, for more complete information about Shineco and the proposed offering. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor will there be any sale of these securities in any state or jurisdiction where such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Shineco, Inc.

Shineco Inc. (“Shineco” or the “Company”) aims to ‘care for a healthy life and improve the quality of life’, by providing safe, efficient and high-quality health and medical products and services to society. Shineco, operating through subsidiaries, has researched and developed 33 vitro diagnostic reagents and related medical devices to date, and the Company also produces and sells healthy and nutritious foods. For more information about Shineco, please visit .

Forward-Looking Statements

This press release includes “forward-looking statements” as defined by U.S. federal securities laws. Words like “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue” and similar expressions are meant to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from the expected results. Therefore, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements and factors that may cause such differences include, without limitation, the risks disclosed in the Company’s Annual Report on Form 10-K filed with the SEC on September 28, 2023, and in the Company’s other filings with the SEC. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Except as required by law, the Company disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this press release.

For more information, please contact:

Shineco,Inc.

Mobile: +86-010-68130220

Precept Investor Relations LLC
David J. Rudnick

Mobile: +1-646-694-8538